Quick drug identification for COVID-19 could serve as a boon, as many countries struggle to contain the deadly virus. Lockdowns and stringent restrictions on the movement of people have had a negative impact, including tremendous losses incurred by companies in the AI in drug discovery market. However, if proper treatment is found for treating COVID-19 patients, it could help in many ways. A University of Michigan research team has used an AI-powered image to identify over 17 existing drugs to reduce coronavirus infection in cells. Such methods and techniques help discover the efficacy of existing drugs against COVID-19, ultimately contributing to the growth of the AI in drug discovery market.
Request a sample to get extensive insights into the AI in Drug Discovery Market
The incidence of chronic diseases is increasing at a rapid pace across the globe. According to the Centers for Disease Control and Prevention (CDC), six in 10 adults in the U.S. have a chronic disease, and four in 10 adults have two or more. Furthermore, the CDC also highlights that chronic diseases such as heart disease and diabetes are the leading causes of death in the U.S. Such statistics shed light on the growing prevalence of chronic diseases and the need to bring down the fatality rate caused due to these diseases.
AI platforms used for drug discovery can prove to be a feasible option for deriving insights into the discovery of drugs to treat and minimize the severity of various chronic diseases. Thus, these factors will led to considerable growth of the AI in drug discovery market during the forecast period of 2021-2031.
To understand how our report can bring difference to your business strategy, Ask for a brochure
The role of AI in oncology is estimated to offer significant growth opportunities. AI can help the researchers understand how cancer cells become resistant to anticancer drugs, eventually leading to drug development and adjust drug use. AI technologies such as machine learning can act as a catalyst in existing anticancer drug research.
Paige’s, an AI diagnostic technology startup is a classic instance of the rising advancements in the oncology segment. The company uses machine learning to enable pathologists to facilitate precise cancer diagnoses through the images of tissue samples. Such developments are expected to fuel the growth of the AI in drug discovery market.
Mindful AI is a fast emerging ideal solution for developing drugs in a more human-centric and responsible manner. Mindful AI is an intention-based approach used for creating effective AI-based technologies. With mindful AI, pharmaceutical companies can not only know about how quickly a drug can be developed but also about how inclusive it is in terms of effectiveness. Thus, the growing popularity of mindful AI in the pharmaceutical industry will present promising growth opportunities, thus driving the overall AI in drug discovery market.
The use of AI in treating neurological disorders could present an array of growth opportunities. Various players in the pharmaceutical industry are collaborating for exploring novel neurological diseases solutions. PharmEnable, the U.K.-based drug discovery company and Sosei, a Japan-based firm, are collaborating to use the Sosei Heprares CPCR-focused drug design platform and PharmEnable’s AI technologies to discover drug leads. Similar developments will assure extensive growth for the AI in drug discovery market.
Stuck in a neck-to-neck competition with other brands? Request a custom report on AI in Drug Discovery Market
Analysts’ viewpoint
The AI in drug discovery market is estimated to expand at a CAGR of 36.1% during the forecast period of 2021-2031. The global market is projected to cross US$ 10.93 Bn by 2031. The cases of chronic diseases, especially cardiovascular disorders and diabetes, are increasing at an accelerated rate, eventually boosting the need for AI in drug discovery platforms. Furthermore, the use of AI in treating neurological disorders will help in increasing the growth rate. Players in the AI in drug discovery market should focus on using Mindful AI to design and develop effective drug discovery platforms. Furthermore, advancements made by AI in findings related to COVID-19 are anticipated to witness substantial growth.
AI in Drug Discovery Market – Segmentation
TMR’s study on the global AI in drug discovery market includes information divided into six segments: offering, technology, drug type, application, end user, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global AI in drug discovery market are discussed in detail.
| Drug Type |
|
| Application |
|
| Technology |
|
| Offering |
|
| End User |
|
| Region |
|
AI in drug discovery market is projected to reach US$ 10.93 Bn By 2031
AI in drug discovery market is anticipated to expand at a CAGR of 36.1% during the forecast period
AI in drug discovery market is driven by increase in pressure on drug manufacturers to reduce drug prices, rise in prevalence of lifestyle diseases and increase in healthcare expenditure
The machine learning segment held significant share of the AI in drug discovery market
Top Key players in AI in drug discovery market are Exscientia, GNS Healthcare, Cloud Pharmaceuticals, Inc., Benevolent AI, PathAI, Inc., BlackThorn Therapeutics, Insilico Medicine, Notable Labs, Standigm, Recursion Pharmaceuticals, and BioSymetrics
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global AI in Drug Discovery Market
4. Market Overview
4.1. Introduction
4.1.1. Market Introduction
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global AI in Drug Discovery Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industry Events (mergers, acquisitions, partnerships, etc.)
5.2. Technological Advancements
5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid /long term impact)
6. Global AI in Drug Discovery Market Analysis and Forecast, by Offering
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Offering, 2017–2031
6.3.1. Software
6.3.2. Services
6.4. Market Attractiveness Analysis, by Offering
7. Global AI in Drug Discovery Market Analysis and Forecast, by Technology
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Technology, 2017–2031
7.3.1. Machine Learning
7.3.2. Other Technologies
7.4. Market Attractiveness Analysis, by Technology
8. Global AI in Drug Discovery Market Analysis and Forecast, by Drug Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Drug Type, 2017–2031
8.3.1. Small Molecules
8.3.2. Large Molecules
8.4. Market Attractiveness Analysis, by Drug Type
9. Global AI in Drug Discovery Market Analysis and Forecast, by Application
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Application, 2017–2031
9.3.1. Oncology
9.3.2. Infectious Diseases
9.3.3. Neurological Disorders
9.3.4. Rare Diseases
9.3.5. Metabolic Diseases
9.3.6. Cardiovascular Diseases
9.3.7. Others
9.4. Market Attractiveness Analysis, by Application
10. Global AI in Drug Discovery Market Analysis and Forecast, by End-user
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. Pharmaceutical & Biotechnology Companies
10.3.2. Contract Research Organizations
10.3.3. Academics & Research
10.3.4. Others
10.4. Market Attractiveness Analysis, by End-user
11. Global AI in Drug Discovery Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Country/Region
12. North America AI in Drug Discovery Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Offering, 2017–2031
12.2.1. Software
12.2.2. Services
12.3. Market Value Forecast, by Technology, 2017–2031
12.3.1. Machine Learning
12.3.2. Other Technologies
12.4. Market Value Forecast, by Drug Type, 2017–2031
12.4.1. Small Molecules
12.4.2. Large Molecules
12.5. Market Value Forecast, by Application, 2017–2031
12.5.1. Oncology
12.5.2. Infectious Diseases
12.5.3. Neurological Disorders
12.5.4. Rare Diseases
12.5.5. Metabolic Diseases
12.5.6. Cardiovascular Diseases
12.5.7. Others
12.6. Market Value Forecast, by End-user, 2017–2031
12.6.1. Pharmaceutical & Biotechnology Companies
12.6.2. Contract Research Organizations
12.6.3. Academics & Research
12.6.4. Others
12.7. Market Value Forecast, by Country, 2017–2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Offering
12.8.2. By Technology
12.8.3. By Drug Type
12.8.4. By Application
12.8.5. By End-user
12.8.6. By Country
13. Europe AI in Drug Discovery Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Offering, 2017–2031
13.2.1. Software
13.2.2. Services
13.3. Market Value Forecast, by Technology, 2017–2031
13.3.1. Machine Learning
13.3.2. Other Technologies
13.4. Market Value Forecast, by Drug Type, 2017–2031
13.4.1. Small Molecules
13.4.2. Large Molecules
13.5. Market Value Forecast, by Application, 2017–2031
13.5.1. Oncology
13.5.2. Infectious Diseases
13.5.3. Neurological Disorders
13.5.4. Rare Diseases
13.5.5. Metabolic Diseases
13.5.6. Cardiovascular Diseases
13.5.7. Others
13.6. Market Value Forecast, by End-user, 2017–2031
13.6.1. Pharmaceutical & Biotechnology Companies
13.6.2. Contract Research Organizations
13.6.3. Academics & Research
13.6.4. Others
13.7. Market Value Forecast, by Country/Sub-region, 2017–2031
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Offering
13.8.2. By Technology
13.8.3. By Drug Type
13.8.4. By Application
13.8.5. By End-user
13.8.6. By Country/Sub-region
14. Asia Pacific AI in Drug Discovery Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Offering, 2017–2031
14.2.1. Software
14.2.2. Services
14.3. Market Value Forecast, by Technology, 2017–2031
14.3.1. Machine Learning
14.3.2. Other Technologies
14.4. Market Value Forecast, by Drug Type, 2017–2031
14.4.1. Small Molecules
14.4.2. Large Molecules
14.5. Market Value Forecast, by Application, 2017–2031
14.5.1. Oncology
14.5.2. Infectious Diseases
14.5.3. Neurological Disorders
14.5.4. Rare Diseases
14.5.5. Metabolic Diseases
14.5.6. Cardiovascular Diseases
14.5.7. Others
14.6. Market Value Forecast, by End-user, 2017–2031
14.6.1. Pharmaceutical & Biotechnology Companies
14.6.2. Contract Research Organizations
14.6.3. Academics & Research
14.6.4. Others
14.7. Market Value Forecast, by Country/Sub-region, 2017–2031
14.7.1. Japan
14.7.2. China
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Offering
14.8.2. By Technology
14.8.3. By Drug Type
14.8.4. By Application
14.8.5. By End-user
14.8.6. By Country/Sub-region
15. Latin America AI in Drug Discovery Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Offering, 2017–2031
15.2.1. Software
15.2.2. Services
15.3. Market Value Forecast, by Technology, 2017–2031
15.3.1. Machine Learning
15.3.2. Other Technologies
15.4. Market Value Forecast, by Drug Type, 2017–2031
15.4.1. Small Molecules
15.4.2. Large Molecules
15.5. Market Value Forecast, by Application, 2017–2031
15.5.1. Oncology
15.5.2. Infectious Diseases
15.5.3. Neurological Disorders
15.5.4. Rare Diseases
15.5.5. Metabolic Diseases
15.5.6. Cardiovascular Diseases
15.5.7. Others
15.6. Market Value Forecast, by End-user, 2017–2031
15.6.1. Pharmaceutical & Biotechnology Companies
15.6.2. Contract Research Organizations
15.6.3. Academics & Research
15.6.4. Others
15.7. Market Value Forecast, by Country/Sub-region, 2017–2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Offering
15.8.2. By Technology
15.8.3. By Drug Type
15.8.4. By Application
15.8.5. By End-user
15.8.6. By Country/Sub-region
16. Middle East & Africa AI in Drug Discovery Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Offering, 2017–2031
16.2.1. Software
16.2.2. Services
16.3. Market Value Forecast, by Technology, 2017–2031
16.3.1. Machine Learning
16.3.2. Other Technologies
16.4. Market Value Forecast, by Drug Type, 2017–2031
16.4.1. Small Molecules
16.4.2. Large Molecules
16.5. Market Value Forecast, by Application, 2017–2031
16.5.1. Oncology
16.5.2. Infectious Diseases
16.5.3. Neurological Disorders
16.5.4. Rare Diseases
16.5.5. Metabolic Diseases
16.5.6. Cardiovascular Diseases
16.5.7. Others
16.6. Market Value Forecast, by End-user, 2017–2031
16.6.1. Pharmaceutical & Biotechnology Companies
16.6.2. Contract Research Organizations
16.6.3. Academics & Research
16.6.4. Others
16.7. Market Value Forecast, by Country/Sub-region, 2017–2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Offering
16.8.2. By Technology
16.8.3. By Drug Type
16.8.4. By Application
16.8.5. By End-user
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player - Competition Matrix (by tier and size of companies)
17.2. Market Share Analysis/Ranking, by Company, 2020
17.3. Company Profiles
17.3.1. Exscientia
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Company Financials
17.3.1.3. Growth Strategies
17.3.1.4. SWOT Analysis
17.3.2. GNS Healthcare
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Company Financials
17.3.2.3. Growth Strategies
17.3.2.4. SWOT Analysis
17.3.3. Cloud Pharmaceuticals, Inc.
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Company Financials
17.3.3.3. Growth Strategies
17.3.3.4. SWOT Analysis
17.3.4. Benevolent AI
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Company Financials
17.3.4.3. Growth Strategies
17.3.4.4. SWOT Analysis
17.3.5. PathAI, Inc.
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Company Financials
17.3.5.3. Growth Strategies
17.3.5.4. SWOT Analysis
17.3.6. Berg Health
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Company Financials
17.3.6.3. Growth Strategies
17.3.6.4. SWOT Analysis
17.3.7. Atomwise
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Company Financials
17.3.7.3. Growth Strategies
17.3.7.4. SWOT Analysis
17.3.8. Insitro
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Company Financials
17.3.8.3. Growth Strategies
17.3.8.4. SWOT Analysis
17.3.9. Cyclica
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Company Financials
17.3.9.3. Growth Strategies
17.3.9.4. SWOT Analysis
17.3.10. BlackThorn Therapeutics
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Company Financials
17.3.10.3. Growth Strategies
17.3.10.4. SWOT Analysis
17.3.11. Insilico Medicine
17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.11.2. Company Financials
17.3.11.3. Growth Strategies
17.3.11.4. SWOT Analysis
17.3.12. Notable Labs
17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.12.2. Company Financials
17.3.12.3. Growth Strategies
17.3.12.4. SWOT Analysis
17.3.13. Standigm
17.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.13.2. Company Financials
17.3.13.3. Growth Strategies
17.3.13.4. SWOT Analysis
17.3.14. Recursion Pharmaceuticals
17.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.14.2. Company Financials
17.3.14.3. Growth Strategies
17.3.14.4. SWOT Analysis
17.3.15. BioSymetrics
17.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.15.2. Company Financials
17.3.15.3. Growth Strategies
17.3.15.4. SWOT Analysis
List of Tables
Table 01: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by Offering, 2017–2031
Table 02: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 03: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 04: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 05: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 06: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 07: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Country, 2017–2031
Table 08: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Offering, 2017–2031
Table 09: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Technology, 2017–2031
Table 10: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 11: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 12: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Offering, 2017–2031
Table 15: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Technology, 2017–2031
Table 16: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 17: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 18: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 19: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 20: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Offering, 2017–2031
Table 21: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Technology, 2017–2031
Table 22: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 23: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 25: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 26: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Offering, 2017–2031
Table 27: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Technology, 2017–2031
Table 28: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 29: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 30: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 31: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 32: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Offering, 2017–2031
Table 33: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Technology, 2017–2031
Table 34: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 35: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 36: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global AI in Drug Discovery Market Value Share, by Offering, 2020
Figure 03: Global AI in Drug Discovery Market Value Share, by Technology, 2020
Figure 04: Global AI in Drug Discovery Market Value Share, by Drug Type, 2020
Figure 05: Global AI in Drug Discovery Market Value Share, by Application, 2020
Figure 06: Global AI in Drug Discovery Market Value Share, by End-user, 2020
Figure 07: Global AI in Drug Discovery Market Value Share, by Indication, 2020
Figure 08: Global AI in Drug Discovery Market Value Share Analysis, by Offering, 2020 and 2031
Figure 09: Global AI in Drug Discovery Market Attractiveness Analysis, by Offering, 2021–2031
Figure 10: Global AI in Drug Discovery Market Value (US$ Mn), by Software, 2017–2031
Figure 11: Global AI in Drug Discovery Market Value (US$ Mn), by Services, 2017–2031
Figure 12: Global AI in Drug Discovery Market Value Share Analysis, by Technology, 2020 and 2031
Figure 13: Global AI in Drug Discovery Market Attractiveness Analysis, by Technology, 2021–2031
Figure 14: Global AI in Drug Discovery Market Value (US$ Mn), by Machine Learning, 2017–2031
Figure 15: Global AI in Drug Discovery Market Value (US$ Mn), by Other Technologies, 2017–2031
Figure 16: Global AI in Drug Discovery Market Value Share Analysis, by Drug Type, 2020 and 2031
Figure 17: Global AI in Drug Discovery Market Attractiveness Analysis, by Drug Type, 2021–2031
Figure 18: Global AI in Drug Discovery Market Value (US$ Mn), by Small Molecules, 2017–2031
Figure 19: Global AI in Drug Discovery Market Value (US$ Mn), by Large Molecules, 2017–2031
Figure 20: Global AI in Drug Discovery Market Value Share Analysis, by Application, 2020 and 2031
Figure 21: Global AI in Drug Discovery Market Attractiveness Analysis, by Application, 2021–2031
Figure 22: Global AI in Drug Discovery Market Value (US$ Mn), by Oncology, 2017–2031
Figure 23: Global AI in Drug Discovery Market Value (US$ Mn), by Infectious Diseases, 2017–2031
Figure 24: Global AI in Drug Discovery Market Value (US$ Mn), by Neurological Disorders, 2017–2031
Figure 25: Global AI in Drug Discovery Market Value (US$ Mn), by Rare Diseases, 2017–2031
Figure 26: Global AI in Drug Discovery Market Value (US$ Mn), by Metabolic Diseases, 2017–2031
Figure 27: Global AI in Drug Discovery Market Value (US$ Mn), by Cardiovascular Diseases, 2017–2031
Figure 28: Global AI in Drug Discovery Market Value (US$ Mn), by Others, 2017–2031
Figure 29: Global AI in Drug Discovery Market Value Share Analysis, by End-user, 2020 and 2031
Figure 30: Global AI in Drug Discovery Market Attractiveness Analysis, by End-user, 2021–2031
Figure 31: Global AI in Drug Discovery Market Value (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2017–2031
Figure 32: Global AI in Drug Discovery Market Value (US$ Mn), by Contract Research Organizations, 2017–2031
Figure 33: Global AI in Drug Discovery Market Value (US$ Mn), by Academics & Research, 2017–2031
Figure 34: Global AI in Drug Discovery Market Value (US$ Mn), by Others, 2017–2031
Figure 35: Global AI in Drug Discovery Market Value Share Analysis, by Region, 2020 and 2031
Figure 36: Global AI in Drug Discovery Market Attractiveness Analysis, by Region, 2021–2031
Figure 37: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 38: North America AI in Drug Discovery Market Value Share (%), by Country, 2020 and 2031
Figure 39: North America AI in Drug Discovery Market Attractiveness Analysis, by Country, 2021–2031
Figure 40: North America AI in Drug Discovery Market Value Share Analysis, by Offering, 2020 and 2031
Figure 41: North America AI in Drug Discovery Market Attractiveness Analysis, by Offering, 2021–2031
Figure 42: North America AI in Drug Discovery Market Value Share Analysis, by Technology, 2020 and 2031
Figure 43: North America AI in Drug Discovery Market Attractiveness Analysis, by Technology, 2021–2031
Figure 44: North America AI in Drug Discovery Market Value Share Analysis, by Drug Type, 2020 and 2031
Figure 45: North America AI in Drug Discovery Market Attractiveness Analysis, by Drug Type, 2021–2031
Figure 46: North America AI in Drug Discovery Market Value Share Analysis, by Application, 2020 and 2031
Figure 47: North America AI in Drug Discovery Market Attractiveness Analysis, by Application, 2021–2031
Figure 48: North America AI in Drug Discovery Market Value Share Analysis, by End-user, 2020 and 2031
Figure 49: North America AI in Drug Discovery Market Attractiveness Analysis, by End-user, 2021–2031
Figure 50: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 51: Europe AI in Drug Discovery Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 52: Europe AI in Drug Discovery Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 53: Europe AI in Drug Discovery Market Value Share Analysis, by Offering, 2020 and 2031
Figure 54: Europe AI in Drug Discovery Market Attractiveness Analysis, by Offering, 2021–2031
Figure 55: Europe AI in Drug Discovery Market Value Share Analysis, by Technology, 2020 and 2031
Figure 56: Europe AI in Drug Discovery Market Attractiveness Analysis, by Technology, 2021–2031
Figure 57: Europe AI in Drug Discovery Market Value Share Analysis, by Drug Type, 2020 and 2031
Figure 58: Europe AI in Drug Discovery Market Attractiveness Analysis, by Drug Type, 2021–2031
Figure 59: Europe AI in Drug Discovery Market Value Share Analysis, by Application, 2020 and 2031
Figure 60: Europe AI in Drug Discovery Market Attractiveness Analysis, by Application, 2021–2031
Figure 61: Europe AI in Drug Discovery Market Value Share Analysis, by End-user, 2020 and 2031
Figure 62: Europe AI in Drug Discovery Market Attractiveness Analysis, by End-user, 2021–2031
Figure 63: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 64: Asia Pacific AI in Drug Discovery Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 65: Asia Pacific AI in Drug Discovery Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 66: Asia Pacific AI in Drug Discovery Market Value Share Analysis, by Offering, 2020 and 2031
Figure 67: Asia Pacific AI in Drug Discovery Market Attractiveness Analysis, by Offering, 2021–2031
Figure 68: Asia Pacific AI in Drug Discovery Market Value Share Analysis, by Technology, 2020 and 2031
Figure 69: Asia Pacific AI in Drug Discovery Market Attractiveness Analysis, by Technology, 2021–203169
Figure 70: Asia Pacific AI in Drug Discovery Market Value Share Analysis, by Drug Type, 2020 and 2031
Figure 71: Asia Pacific AI in Drug Discovery Market Attractiveness Analysis, by Drug Type, 2021–2031
Figure 72: Asia Pacific AI in Drug Discovery Market Value Share Analysis, by Application, 2020 and 2031
Figure 73: Asia Pacific AI in Drug Discovery Market Attractiveness Analysis, by Application, 2021–2031
Figure 74: Asia Pacific AI in Drug Discovery Market Value Share Analysis, by End-user, 2020 and 2031
Figure 75: Asia Pacific AI in Drug Discovery Market Attractiveness Analysis, by End-user, 2021–2031
Figure 76: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 77: Latin America AI in Drug Discovery Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 78: Latin America AI in Drug Discovery Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 79: Latin America AI in Drug Discovery Market Value Share Analysis, by Offering, 2020 and 2031
Figure 80: Latin America AI in Drug Discovery Market Attractiveness Analysis, by Offering, 2021–203180
Figure 81: Latin America AI in Drug Discovery Market Value Share Analysis, by Technology, 2020 and 2031
Figure 82: Latin America AI in Drug Discovery Market Attractiveness Analysis, by Technology, 2021–2031
Figure 83: Latin America AI in Drug Discovery Market Value Share Analysis, by Drug Type, 2020 and 2031
Figure 84: Latin America AI in Drug Discovery Market Attractiveness Analysis, by Drug Type, 2021–2031
Figure 85: Latin America AI in Drug Discovery Market Value Share Analysis, by Application, 2020 and 2031
Figure 86: Latin America AI in Drug Discovery Market Attractiveness Analysis, by Application, 2021–2031
Figure 87: Latin America AI in Drug Discovery Market Value Share Analysis, by End-user, 2020 and 2031
Figure 88: Latin America AI in Drug Discovery Market Attractiveness Analysis, by End-user, 2021–2031
Figure 89: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 90: Middle East & Africa AI in Drug Discovery Market Value Share (%), by Country/Sub-Region, 2020 and 2031
Figure 91: Middle East & Africa AI in Drug Discovery Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 92: Middle East & Africa AI in Drug Discovery Market Value Share Analysis, by Offering, 2020 and 2031
Figure 93: Middle East & Africa AI in Drug Discovery Market Attractiveness Analysis, by Offering, 2021–2031
Figure 94: Middle East & Africa AI in Drug Discovery Market Value Share Analysis, by Technology, 2020 and 2031
Figure 95: Middle East & Africa AI in Drug Discovery Market Attractiveness Analysis, by Technology, 2021–2031
Figure 96: Middle East & Africa AI in Drug Discovery Market Value Share Analysis, by Drug Type, 2020 and 2031
Figure 97: Middle East & Africa AI in Drug Discovery Market Attractiveness Analysis, by Drug Type, 2021–2031
Figure 98: Middle East & Africa AI in Drug Discovery Market Value Share Analysis, by Application, 2020 and 2031
Figure 99: Middle East & Africa AI in Drug Discovery Market Attractiveness Analysis, by Application, 2021–2031
Figure 100: Middle East & Africa AI in Drug Discovery Market Value Share Analysis, by End-user, 2020 and 2031
Figure 101: Middle East & Africa AI in Drug Discovery Market Attractiveness Analysis, by End-user, 2021–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
AI in Drug Discovery Market Forecast Report, 2021-2031
*86 figures and 60 tables includes